| A decade of nutraceutical patents: where are we now in 2018? |
49 |
| Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018) |
33 |
| Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011-2016) |
29 |
| Sulfonamide inhibitors: a patent review 2013-present |
26 |
| Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases |
22 |
| Biomedical applications of prokaryotic carbonic anhydrases |
21 |
| Benzoxaborole compounds for therapeutic uses: a patent review (2010-2018) |
19 |
| A patent review of arginine methyltransferase inhibitors (2010-2018) |
18 |
| Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019 |
18 |
| Bioactivity and pharmacological properties of alpha-mangostin from the mangosteen fruit: a review |
18 |
| Indazole derivatives and their therapeutic applications: a patent review (2013-2017) |
18 |
| Retinoic acid receptor-related orphan receptor gamma-t (ROR gamma t) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present) |
17 |
| A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018) |
17 |
| Marine natural products as source of new drugs: a patent review (2015-2018) |
14 |
| MCL-1 inhibitors ? where are we now (2019)? |
14 |
| Quorum sensing inhibitors: a patent review (2014-2018) |
13 |
| Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018) |
13 |
| Farnesoid X receptor modulators 2014-present: a patent review |
13 |
| A patent review of IDO1 inhibitors for cancer |
13 |
| An updated patent review on P-glycoprotein inhibitors (2011-2018) |
12 |
| MAO inhibitors and their wider applications: a patent review |
12 |
| Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review |
11 |
| FAK inhibitors in Cancer, a patent review |
11 |
| Therapeutic potential of glycyrrhetinic acids: a patent review (2010-2017) |
11 |
| Therapeutic potential of Panax ginseng and its constituents, ginsenosides and gintonin, in neurological and neurodegenerative disorders: a patent review |
11 |
| Therapeutic potential of oxazole scaffold: a patent review (2006-2017) |
10 |
| Serine protease inhibitors to treat inflammation: a patent review (2011-2016) |
10 |
| Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018) |
10 |
| Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017) |
10 |
| A patent review of the ubiquitin ligase system: 2015-2018 |
10 |
| Usnic acid and its derivatives for pharmaceutical use: a patent review (2000-2017) |
10 |
| Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018) |
9 |
| A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications |
9 |
| Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018) |
9 |
| ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents |
9 |
| Saffron and its derivatives, crocin, crocetin and safranal: a patent review |
9 |
| c-Met kinase inhibitors: an update patent review (2014-2017) |
9 |
| FXR modulators for enterohepatic and metabolic diseases |
9 |
| Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications |
8 |
| Aldose reductase inhibitors: 2013-present |
8 |
| HDAC inhibitors: a 2013-2017 patent survey |
8 |
| An updated patent review of therapeutic applications of chalcone derivatives (2014-present) |
8 |
| Circulating miRNAs as biomarkers for early diagnosis of coronary artery disease |
7 |
| Pharmacological and biotechnological advances with Rosmarinus officinalis L |
7 |
| Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1 |
7 |
| Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018) |
7 |
| Carbonic anhydrases as disease markers |
7 |
| A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018) |
6 |
| An update on liposomes in drug delivery: a patent review (2014-2018) |
6 |
| Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review |
6 |
